Altimmune (NASDAQ:ALT) Price Target Lowered to $11.00 at Citizens Jmp

Altimmune (NASDAQ:ALT) had its price objective lowered by stock analysts at Citizens Jmp from $14.00 to $11.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective points to a potential upside of 272.25% from the stock’s current price.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. HC Wainwright lifted their target price on shares of Altimmune from $12.00 to $25.00 and gave the company a “buy” rating in a report on Monday, March 16th. Barclays began coverage on shares of Altimmune in a research report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price target for the company. B. Riley Financial lowered their price target on Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a report on Friday, March 6th. Finally, Truist Financial began coverage on Altimmune in a research report on Wednesday, March 18th. They issued a “buy” rating and a $12.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.50.

Altimmune Trading Down 2.2%

NASDAQ:ALT traded down $0.07 during trading hours on Thursday, reaching $2.96. 447,378 shares of the company were exchanged, compared to its average volume of 4,493,037. The company has a debt-to-equity ratio of 0.15, a current ratio of 18.55 and a quick ratio of 18.55. The firm has a market cap of $384.45 million, a price-to-earnings ratio of -2.94 and a beta of 0.18. The stock has a 50 day simple moving average of $3.31 and a 200 day simple moving average of $4.12. Altimmune has a 52-week low of $2.56 and a 52-week high of $7.73.

Altimmune (NASDAQ:ALT) last issued its earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%. As a group, analysts predict that Altimmune will post -1 EPS for the current year.

Insider Buying and Selling at Altimmune

In other news, CEO Jerome Benedict Durso purchased 20,000 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was acquired at an average cost of $3.54 per share, with a total value of $70,800.00. Following the acquisition, the chief executive officer owned 32,500 shares in the company, valued at approximately $115,050. This trade represents a 160.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.60% of the company’s stock.

Institutional Trading of Altimmune

Large investors have recently modified their holdings of the business. SBI Securities Co. Ltd. lifted its stake in shares of Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after acquiring an additional 1,928 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after purchasing an additional 2,241 shares in the last quarter. Concurrent Investment Advisors LLC grew its stake in Altimmune by 10.4% during the 4th quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock valued at $96,000 after purchasing an additional 2,500 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Altimmune by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock worth $108,000 after purchasing an additional 2,748 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in Altimmune by 4.0% during the 4th quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock worth $289,000 after purchasing an additional 3,047 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.